Yes, complement is activated by immune complexes in lupus nephritis
In lupus nephritis, the complement system is definitively activated by immune complex deposition, representing a central pathogenic mechanism that drives glomerular and tubulointerstitial injury. 1, 2
Pathogenic Mechanism
Lupus nephritis is classified as an immune complex-mediated glomerulonephritis where:
- Autoantibodies bind to nuclear antigens (particularly anti-dsDNA) forming circulating immune complexes
- These immune complexes deposit in glomerular structures (mesangium, subendothelial, subepithelial spaces)
- Complement activation occurs via the classical pathway when IgG-containing immune complexes bind C1q 2, 3
- Granular immunofluorescence pattern is characteristic, showing IgG and complement components (C3, C1q) deposited in glomeruli 1
This contrasts sharply with pauci-immune glomerulonephritis (ANCA-associated) which shows minimal immune deposits, or anti-GBM disease which shows linear rather than granular deposits 1.
Clinical Evidence of Complement Activation
The 2023 expert panel guidelines emphasize several markers of active complement consumption in lupus nephritis 4:
- Low C1q levels are associated with SLE flare-ups
- Anti-C1q antibodies are found in almost 100% of patients with active lupus nephritis 4
- Complement levels should always be monitored during follow-up, even if previously normal 4
- The negative predictive value of anti-C1q is critical—patients are unlikely to flare in the absence of these antibodies 4
Dual Role of Complement
Important caveat: Complement plays a paradoxical dual role in SLE 3, 5, 6:
- Protective role: Hereditary deficiencies of early classical pathway components (C1q, C4) actually increase susceptibility to developing SLE
- Pathogenic role: Once immune complexes form, complement activation causes tissue injury through inflammatory mediators, membrane attack complex formation, and leukocyte recruitment
Pathophysiologic Classification
The KDIGO 2021 guidelines 2 recommend classifying glomerular diseases by immunofluorescence pattern:
- Immunoglobulin-positive (with complement) = immune complex-mediated disease → includes lupus nephritis, infection-related GN, cryoglobulinemia
- Complement-dominant (minimal immunoglobulin) = C3 glomerulopathy → alternative pathway dysregulation
- Negative immunofluorescence = consider thrombotic microangiopathy
Lupus nephritis definitively falls into the first category, with both immunoglobulin and complement deposition visible on biopsy 2.
Beyond Classical Pathway Activation
Recent evidence 3 demonstrates that all three complement pathways may be involved in lupus nephritis:
- Classical pathway (primary mechanism via immune complexes)
- Alternative pathway (amplification loop)
- Lectin pathway (additional activation route)
This multi-pathway involvement explains why complement consumption is so prominent in active disease and why anti-complement therapies are being investigated 7, 3.
Monitoring Implications
Based on the 2023 recommendations 4:
- Monitor anti-dsDNA and complement levels at every follow-up visit
- Use quantitative assays performed by the same laboratory
- Consider anti-C1q antibodies as disease activity biomarkers, particularly for predicting renal flares
- In anti-dsDNA negative lupus nephritis (which can occur), consider anti-nucleosome or anti-histone antibodies 4
The statement is correct: complement activation against immune complexes is a defining pathogenic feature of lupus nephritis, distinguishing it from other forms of glomerulonephritis and providing both diagnostic markers and therapeutic targets.